Prevention of deep vein thrombosis following total hip replacement surgery by Orgaran. Summary.
ten Cate
J W
JW
Center for Haemostasis, Academic Medical Center, Amsterdam, The Netherlands.
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004087:Dihydroergotamine / Q000627:therapeutic use; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006496:Heparinoids / Q000627:therapeutic use*; D006497:Heparan Sulfate; D006622:Hip Prosthesis / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D011655:Pulmonary Embolism / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D016037:Single-Blind Method; D013924:Thrombophlebitis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004087:Dihydroergotamine; D006025:Glycosaminoglycans; D006493:Heparin; D006496:Heparinoids; D006497:Heparan Sulfate; C035838:danaparoid